Acquisitive Pierre Fabre doubles down on oncology strategy

12 September 2023
pierre_fabre_large

Dermatology and cosmetics company Pierre Fabre Laboratories has bought oncology specialist Vertical Bio, thus adding VERT-002 to its discovery pipeline.

The French firm has a long track record in the treatment of cancer, beginning with the launch of a chemotherapy product several decades ago.

Building on this, the group has now made oncology its top strategic priority, focusing 80% of its R&D spend in this area, leading to a more than doubling of revenues from 2019, up to around half a billion dollars.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology